HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)

Phase 1 Study of HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer

The purpuse of this study is to assess toxicities of angiogenic peptide vaccine therapy with gemcitabine in treating HLA-A*0201 restricted patient with non-resectable pancreatic cancer.

The prognosis of pancreatic cancer is extremely poor even with extensive surgery, chemotherapy or radiation. It has been required development of new treatment modalities. Immunotherapy is one of the encouraging modalities for cancer patients. The investigators have to assess its toxicities and immune responsiveness.

Inclusion Criteria:

• locally advanced or metastatic pancreatic cancer precluding curative surgical resection and recurrent pancreatic cancer
• Measurable disease by CT scan
• ECOG performance status 0-2
• Life expectancy > 3 months
• laboratory values as follows: 2,000/mm3 < WBC < 15,000/mm3, Platelet count >75,000/mm3, Total Bilirubin <1.5 mg/dl, Asparate transaminase <150IU/L, Alanine transaminase < 150 IU/L, Creatinine < 3.0mg/dl
• HLA-A*0201
• Able and willing to give valid written infromed consent

Exclusion Criteria:

• Pregnancy (women of childbearing potential: Refusal or inability to use effective means of contraception)
• Breast-feeder
• Active or uncontrolled infection
• Prior chemotherapy, radiation therapy, or immunotherapy within 4 weeks
• Serious or uncured wound
• Active or uncontrolled other malignancy
• Steroids or immunosuppressing agent dependent status
• Interstitial pneumonia
• Ileus
• Decision of unsuitableness by principal investigator or physician-in-charge